Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients

Authors: Xiaojie Tan, Songqin He, Yifang Han, Yongwei Yu, Jianru Xiao, Danfeng Xu, Guoping Wang, Yan Du, Wenjun Chang, Jianhua Yin, Tong Su, Jianguo Hou, Guangwen Cao

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstracts

Background

Clear cell renal cell carcinoma (ccRCC) cell lines with distinct metastatic potential are essential to study the mechanism of ccRCC metastasis. However, none of them originated from Chinese.

Methods

Primary cell cultures were performed using a primary tumor of a 49-year-old male ccRCC patient and a metastatic tumor of a 62-year-old male patient who had received nephrectomy to excise primary ccRCC 10 years ago. Cell growth, microstructure, cytogenetics, cytometry, expression of metastasis-associated molecules, tumorigenesis and metastasis were subsequently characterized.

Results

Two successive cell lines named NRCC from the primary ccRCC and MRCC from the metastatic ccRCC were established, respectively. Compared to NRCC, MRCC exhibited stronger anchorage-independent growth and invasion potentials and contained more glycogen granules in the cytoplasm. Gains of chromosomes and some translocations were the major chromosomal aberrations in both cell strains. CD24 expression was more frequent in MRCC than in NRCC and the same was true for CD56. The transcriptional levels of TNF α, IL-6, VEGF, HIF2 α, MMP2, and RhoC were significantly higher in MRCC than in NRCC. Cytosolic IκBα protein was more degraded in MRCC than in NRCC following TNFα treatment. Both cell lines had strong tumorigenicity in athymic nude mice. However, MRCC had strong potential in generating metastasis to lung and hemorrhagic ascites than NRCC following orthotopic transplantations.

Conclusions

Cancer cells isolated from metastatic ccRCC have more malignant and metastatic potential than those from the primary tumor from the patients who shared the similar race background. Establishment of MRCC and NRCC may provide suitable models with which to investigate molecular mechanisms of ccRCC metastasis.
Appendix
Available only for authorised users
Literature
1.
Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol. 2011, 60: 615-621. 10.1016/j.eururo.2011.06.049.CrossRefPubMed
2.
Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, de Kernion JB, Figlin RA, Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002, 20: 4559-4566. 10.1200/JCO.2002.05.111.CrossRefPubMed
3.
Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010, 116: 1272-1280. 10.1002/cncr.24864.CrossRefPubMed
4.
Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, Angevin E, Caignard A: Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer. 2004, 109: 393-401. 10.1002/ijc.11730.CrossRefPubMed
5.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group:: : Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007, 356: 125-134. 10.1056/NEJMoa060655.CrossRefPubMed
6.
Wang G, Hou J, Ma L, Xie J, Yin J, Xu D, Chang W, Tan X, Su T, Zhang H, Cao G: Risk factor for clear cell renal cell carcinoma in Chinese population: a case–control study. Cancer Epidemiol. 2012, 36: 177-182. 10.1016/j.canep.2011.09.006.CrossRefPubMed
7.
Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 1986, 46: 4109-4115.PubMed
8.
Yano H, Maruiwa M, Sugihara S, Kojiro M, Noda S, Eto K: Establishment and characterization of a new human renal cell carcinoma cell line (KRC/Y). In Vitro Cell Dev Biol. 1988, 24: 9-16. 10.1007/BF02623810.CrossRefPubMed
9.
Krishnan B, Truong LD: Renal epithelial neoplasms: the diagnostic implications of electron microscopic study in 55 cases. Hum Pathol. 2002, 33: 68-79. 10.1053/hupa.2002.30210.CrossRefPubMed
10.
Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G: Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 2008, 22: 3696-3705. 10.1096/fj.08-102590.CrossRefPubMed
11.
Medina Villaamil V, Aparicio Gallego G, Valbuena Rubira L, García Campelo R, Valladares-Ayerbes M, Grande Pulido E, Victoria Bolós M, Santamarina Caínzos I, Antón Aparicio LM: Fructose transporter GLUT5 expression in clear renal cell carcinoma. Oncol Rep. 2011, 25: 315-323.CrossRefPubMed
12.
13.
Varga Z, Caduff R: Glycogen-rich carcinomas of the breast display unique characteristics with respect to proliferation and the frequency of oligonucleosomal fragments. Breast Cancer Res Treat. 1999, 57: 215-219. 10.1023/A:1006285819701.CrossRefPubMed
14.
Steiner G, Sidransky D: Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites. Am J Pathol. 1996, 149: 1791-1795.PubMedCentralPubMed
15.
Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE: Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res. 2009, 15: 7582-7592. 10.1158/1078-0432.CCR-09-2131.PubMedCentralCrossRefPubMed
16.
Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, He W, Zeng L, Xing M, Wu R, Jiang H, Liu X, Cao D, Guo G, Hu X, Gui Y, Li Z, Xie W, Sun X, Shi M, Cai Z, Wang B, Zhong M, Li J, Lu Z, Gu N: Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 2012, 148: 886-895. 10.1016/j.cell.2012.02.025.CrossRefPubMed
17.
Chi A, Shirodkar SP, Escudero DO, Ekwenna OO, Yates TJ, Ayyathurai R, Garcia-Roig M, Gahan JC, Manoharan M, Bird VG, Lokeshwar VB: Molecular characterization of kidney cancer: Association of hyaluronic acid family with histological subtypes and metastasis. Cancer. 2012, 118: 2394-2402. 10.1002/cncr.26520.PubMedCentralCrossRefPubMed
18.
D’Alterio C, Cindolo L, Portella L, Polimeno M, Consales C, Riccio A, Cioffi M, Franco R, Chiodini P, Cartenì G, Mirone V, Longo N, Marra L, Perdonà S, Claudio L, Mascolo M, Staibano S, Falsaperla M, Puglisi M, Martignoni G, Ficarra V, Castello G, Scala S: Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle. 2010, 9: 4492-4500.CrossRefPubMed
19.
Lee HJ, Kim DI, Kwak C, Ku JH, Moon KC: Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology. 2008, 72: 603-607. 10.1016/j.urology.2008.01.061.CrossRefPubMed
20.
Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G: Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 2012, 48: 1977-1987. 10.1016/j.ejca.2012.01.015.CrossRefPubMed
21.
Daniel L, Bouvier C, Chetaille B, Gouvernet J, Luccioni A, Rossi D, Lechevallier E, Muracciole X, Coulange C, Figarella-Branger D: Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior. Hum Pathol. 2003, 34: 528-532. 10.1016/S0046-8177(03)00178-3.CrossRefPubMed
22.
Ho A, Fusenig N: Cancer stem cells: a promising concept and therapeutic challenge. Int J Cancer. 2011, 129: 2309-10.1002/ijc.26409.CrossRefPubMed
23.
Cabarcas SM, Mathews LA, Farrar WL: The cancer stem cell niche–there goes the neighborhood?. Int J Cancer. 2011, 129: 2315-2327. 10.1002/ijc.26312.CrossRefPubMed
24.
Fukata S, Inoue K, Kamada M, Kawada C, Furihata M, Ohtsuki Y, Shuin T: Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer. 2005, 103: 931-942. 10.1002/cncr.20887.CrossRefPubMed
25.
Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP: Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer. 2012, 130: 2693-2702. 10.1002/ijc.26303.CrossRefPubMed
26.
Abe H, Kamai T, Tsujii T, Nakamura F, Mashidori T, Mizuno T, Tanaka M, Tatsumiya K, Furuya N, Masuda A, Yamanishi T, Yoshida K: Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res. 2008, 29: 155-161. 10.2220/biomedres.29.155.CrossRefPubMed
27.
Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, Cha TL, Sun GH: Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci. 2008, 99: 905-913. 10.1111/j.1349-7006.2008.00756.x.CrossRefPubMed
28.
Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King DM, Eisen T, Corringham R, DeWitte M, Balkwill F, Gore M: Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 2007, 25: 4542-4549. 10.1200/JCO.2007.11.2136.CrossRefPubMed
29.
Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC: HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007, 11: 335-347. 10.1016/j.ccr.2007.02.006.PubMedCentralCrossRefPubMed
30.
Choi H, Chun YS, Kim TY, Park JW: HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin. Cancer Res. 2010, 70: 10101-10111. 10.1158/0008-5472.CAN-10-0505.CrossRefPubMed
31.
Sourbier C, Danilin S, Lindner V, Steger J, Rothhut S, Meyer N, Jacqmin D, Helwig JJ, Lang H, Massfelder T: Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res. 2007, 67: 11668-11676. 10.1158/0008-5472.CAN-07-0632.CrossRefPubMed
32.
Tan X, Zhai Y, Chang W, Hou J, He S, Lin L, Yu Y, Xu D, Xiao J, Ma L, Wang G, Cao T, Cao G: Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma. Int J Cancer. 2008, 123: 1080-1088. 10.1002/ijc.23637.CrossRefPubMed
33.
Rumpler Y, Andriaholinirina N, Warter S, Hauwy M, Rabarivola C: Phylogenetic history of the Sifakas (Propithecus: Lemuriformes) derived from cytogenetic studies. Chromosome Res. 2004, 12: 453-463.CrossRefPubMed
34.
Li X, Tan X, Yu Y, Chen H, Chang W, Hou J, Xu D, Ma L, Cao G: D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta. Cancer. 2011, 117: 4201-4211. 10.1002/cncr.26028.CrossRefPubMed
35.
Sun W, Tan X, Shi Y, Xu G, Mao R, Gu X, Fan Y, Yu Y, Burlingame S, Zhang H, Rednam SP, Lu X, Zhang T, Fu S, Cao G, Qin J, Yang J: USP11 negatively regulates TNFalpha-induced NF-kappaB activation by targeting on IkappaBalpha. Cell Signal. 2010, 22: 386-394. 10.1016/j.cellsig.2009.10.008.PubMedCentralCrossRefPubMed
36.
An Z, Jiang P, Wang X, Moossa AR, Hoffman RM: Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin Exp Metastasis. 1999, 17: 265-270. 10.1023/A:1006654600095.CrossRefPubMed
Metadata
Title
Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients
Authors
Xiaojie Tan
Songqin He
Yifang Han
Yongwei Yu
Jianru Xiao
Danfeng Xu
Guoping Wang
Yan Du
Wenjun Chang
Jianhua Yin
Tong Su
Jianguo Hou
Guangwen Cao
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-20

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue

Primary research

Genistein promotes cell death of ethanol-stressed HeLa cells through the continuation of apoptosis or secondary necrosis

Primary research

Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours

Primary research

3,4-dihydroxyphenyl acetic acid and (+)-epoxydon isolated from marine algae-derived microorganisms induce down regulation of epidermal growth factor activated mitogenic signaling cascade in Hela cells

Primary research

FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia

Primary research

Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells

Primary research

Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: Does the response involve senescence? The possible role of vimentin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits